Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Treace Medical Concepts (TMCI) EBIT Margin (2020 - 2026)

Treace Medical Concepts filings provide 6 years of EBIT Margin readings, the most recent being 9.47% for Q4 2025.

  • On a quarterly basis, EBIT Margin fell 918.0% to 9.47% in Q4 2025 year-over-year; TTM through Dec 2025 was 25.46%, a 114.0% increase, with the full-year FY2025 number at 25.46%, up 114.0% from a year prior.
  • EBIT Margin hit 9.47% in Q4 2025 for Treace Medical Concepts, up from 31.22% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 0.3% in Q4 2024 to a low of 48.1% in Q2 2024.
  • Median EBIT Margin over the past 5 years was 30.38% (2023), compared with a mean of 26.08%.
  • Biggest five-year swings in EBIT Margin: plummeted -3182bps in 2021 and later surged 1228bps in 2025.
  • Treace Medical Concepts' EBIT Margin stood at 16.74% in 2021, then skyrocketed by 58bps to 7.03% in 2022, then crashed by -55bps to 10.9% in 2023, then surged by 97bps to 0.3% in 2024, then crashed by -3090bps to 9.47% in 2025.
  • The last three reported values for EBIT Margin were 9.47% (Q4 2025), 31.22% (Q3 2025), and 35.82% (Q2 2025) per Business Quant data.